| Series Title | European Voice |
|---|---|
| Series Details | Vol.9, No.16, 30.4.03, p15 |
| Publication Date | 30/04/2003 |
| Content Type | News |
|
Date: 30/04/03 GLAXOSMITHKLINE announced on Monday that it was halving the price of its main AIDS drug, Combivir, for poor countries to the annual equivalent of less than €300 per patient. However, it will still be more than €50 more expensive than a generic version of the drug by India's Ranbaxy. GSK, which had been under pressure from campaigners to cut the price of Combivir, indicated that it would make no profit on the drug in poor countries. GlaxoSmithKline announced on 28 April 2003 that it was halving the price of its main AIDS drug, Combivir, for poor countries to the annual equivalent of less than EUR 300 per patient. |
|
| Subject Categories | Health, Politics and International Relations |
| Countries / Regions | South Africa |
